Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 6NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma 5Neuroblastoma 5Central Nervous System Neoplasms 4Brain Neoplasms 4Hodgkin Disease 3Teratoma 2Leukemia 2Ganglioneuroblastoma 2Astrocytoma 2Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sertoli-Leydig Cell Tumor 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian gynandroblastoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Malignant mesenchymal tumor 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Granulosa cell tumor of the ovary 1

Interventions

Vinorelbine 4Dexamethasone 4Filgrastim 3Vincristine 2Peripheral Blood Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fenretinide 2Etoposide 2Cytarabine 2Carmustine 2Bortezomib 2zanubrutinib 1relatlimab 1pomalidomide 1pegaspargase 1palbociclib 1liposomal amphotericin B 1ixazomib 1irinotecan sucrosofate 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1etoposide phosphate 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrence × etoposide phosphate × Clear all
NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Children's Oncology Group

Phase 2/3 Completed
24 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡